Cytek Biosciences Share Holder Equity 2021-2025 | CTKB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytek Biosciences share holder equity from 2021 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytek Biosciences share holder equity from 2021 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$243.4B
Amgen (AMGN)	$156.3B
Gilead Sciences (GILD)	$147.7B
Vertex Pharmaceuticals (VRTX)	$100.1B
Bristol Myers Squibb (BMY)	$97.3B
CSL (CSLLY)	$85B
GSK (GSK)	$80B
Regeneron Pharmaceuticals (REGN)	$60B
Alnylam Pharmaceuticals (ALNY)	$58B
Argenex SE (ARGX)	$39.9B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$20.5B
Biogen (BIIB)	$19.8B
Incyte (INCY)	$16.8B
Illumina (ILMN)	$15.4B
Genmab (GMAB)	$14.7B
Genmab (GNMSF)	$14.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.4B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B
Halozyme Therapeutics (HALO)	$7.7B